Santa Fe BioLabs currently has operations in Fort Worth, Texas, USA. Santa Fe BioLabs is engaged in the discovery and development of novel compounds and treatments of microbial infection and detection, cancer, aging, Alzheimer's disease, and agricultural pests. A recent focus is the merging global health threat Candida auris. Additionally, science-based innovative health and personal care products are being developed. Its consulting division provides contract services to test antimicrobials, identify toxic or genotoxic activities and validate targets of novel drugs.
Santa Fe BioLabs offers grant writing, patent consultation services as well as linguistic services (focus on translation/proof-reading/quality management of English/German life science texts).